Ravagalimab represents a significant step in the treatment of disease. This biologic selectively inhibits the role of this specific protein, a molecule involved in inflammation. Early clinical trials have shown encouraging results, particularly in autoimmune diseases such as skin disorders. The how it works offers a unique potential to control the